Overview

PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma

Status:
Active, not recruiting

Trial end date:
2022-06-15

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the overall response rate (ORR) of von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) tumors in VHL patients treated with PT2385.

Phase:

Phase 2

Details

Lead Sponsor:

Peloton Therapeutics, Inc.

Collaborator:

National Institutes of Health (NIH)